Quintet Private Bank Europe S.A. Boosts Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Quintet Private Bank Europe S.A. raised its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 37,702 shares of the company's stock after purchasing an additional 857 shares during the quarter. Eli Lilly and Company accounts for 1.8% of Quintet Private Bank Europe S.A.'s portfolio, making the stock its 18th largest position. Quintet Private Bank Europe S.A.'s holdings in Eli Lilly and Company were worth $31,138,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in LLY. Mascagni Wealth Management Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter valued at about $43,000. FPC Investment Advisory Inc. grew its stake in Eli Lilly and Company by 358.3% during the 4th quarter. FPC Investment Advisory Inc. now owns 55 shares of the company's stock valued at $45,000 after purchasing an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. purchased a new stake in Eli Lilly and Company during the 4th quarter valued at about $48,000. Capital A Wealth Management LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at about $63,000. Finally, Bellwether Advisors LLC purchased a new stake in Eli Lilly and Company during the 4th quarter valued at about $66,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

NYSE LLY traded up $6.53 during trading hours on Friday, reaching $818.56. The company's stock had a trading volume of 2,753,537 shares, compared to its average volume of 3,651,762. The firm has a market capitalization of $775.78 billion, a price-to-earnings ratio of 69.90, a P/E/G ratio of 1.40 and a beta of 0.41. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The company's 50-day moving average is $773.53 and its two-hundred day moving average is $801.30.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.58 EPS. On average, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.73%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 48.82%.

Wall Street Analyst Weigh In

LLY has been the topic of several research analyst reports. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the company from $1,150.00 to $700.00 in a report on Monday, April 28th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, UBS Group decreased their price objective on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $1,011.37.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.